Insulin-like Growth Factor-I (IGF-I) and IGF-binding Proteins Blood Serum Levels in Women with Early- and Late-stage Breast Cancer: Mutual Relationship and Possible Correlations with Patients' Hormonal Status

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 1995 Jan 1

PMID 7593132

Citations 3

Authors

R E Favoni

A DE CUPIS

A Perrotta

S Sforzini

D Amoroso

F Pensa

L Miglietta

Affiliations

Soon will be listed here.

Abstract

The pathogenesis and progression of breast cancer involve complex interactions between hormones and polypeptide growth factors such as insulin-like growth factor-I (IGF-I). IGF-I has been found in stromal fibroblasts derived from malignant and benign breast tissue and it is a mitogen for several breast cancer cell lines. It circulates bound to specific high-affinity binding proteins, which could act as either positive or negative modulators of tumorigenesis. This study has been addressed to characterize IGF-I and its binding proteins in the serum of 85 unselected patients with early breast cancer. The IGF-I concentration was assessed by radioimmunoassay of 69 out of 85 samples before and after dissociation of the IGF-I and IGF-binding protein (IGF-BP) complex whereas IGF-BP of all 85 sera were analyzed by Western ligand blotting; estradiol and progesterone were measured by radioimmunoassay in native serum samples. In our study no differences in IGF-I serum levels between pre- and post-menopausal patients were observed. Patients with higher estradiol and progesterone serum levels did not present different IGF-I concentrations compared to patients with lower serum levels. Furthermore, IGF-I median values were not found to depend on estrogen receptor (ER) status. A heterogeneous quali-quantitative molecular pattern of binding proteins was detected: IGF-BP3 and IGF-BP1 were the most and the least expressed respectively. No correlations between ER status, or parameters related to the hormonal status, and IGF-I or binding proteins expression were observed. No significant differences in IGF-I concentration and IGF-BP expression were observed between cancer patients and a control group matched for age and menopausal status. Finally, preliminary collection of 20 sera derived from patients with late breast cancer was analyzed for IGF-I and its binding proteins content.

Citing Articles

The insulin-like growth factor system and its receptors: A potential novel anticancer target.

Lindsay C, Evans T Biologics. 2009; 2(4):855-64.

PMID: 19707463 PMC: 2727903. DOI: 10.2147/btt.s3841.

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

Favoni R, DE CUPIS A, Bruno S, Yee D, Ferrera A, Pirani P Br J Cancer. 1998; 77(12):2138-47.

PMID: 9649125 PMC: 2150424. DOI: 10.1038/bjc.1998.358.

Breast cancer: further metabolic-endocrine risk markers?.

STOLL B Br J Cancer. 1997; 76(12):1652-4.

PMID: 9413957 PMC: 2228209. DOI: 10.1038/bjc.1997.612.

References

Figueroa J, Yee D . The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res Treat. 1992; 22(1):81-90. DOI: 10.1007/BF01833336. View

Scott C, Martin J, BAXTER R . Rat hepatocyte insulin-like growth factor I and binding protein: effect of growth hormone in vitro and in vivo. Endocrinology. 1985; 116(3):1102-7. DOI: 10.1210/endo-116-3-1102. View

Klapper D, Svoboda M, Van Wyk J . Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology. 1983; 112(6):2215-7. DOI: 10.1210/endo-112-6-2215. View

RUDMAN D, Feller A, Nagraj H, Gergans G, Lalitha P, GOLDBERG A . Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990; 323(1):1-6. DOI: 10.1056/NEJM199007053230101. View

Elgin R, Busby Jr W, Clemmons D . An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci U S A. 1987; 84(10):3254-8. PMC: 304847. DOI: 10.1073/pnas.84.10.3254. View

Zapf J, FROESCH E . Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Horm Res. 1986; 24(2-3):121-30. DOI: 10.1159/000180551. View

Favoni R, DE CUPIS A, Ravera F, Cantoni C, Pirani P, Ardizzoni A . Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer. 1994; 56(6):858-66. DOI: 10.1002/ijc.2910560618. View

Arteaga C, Kitten L, Coronado E, Jacobs S, Kull Jr F, Allred D . Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989; 84(5):1418-23. PMC: 304004. DOI: 10.1172/JCI114315. View

BAXTER R, Martin J . Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res. 1989; 1(1):49-68. DOI: 10.1016/0955-2235(89)90041-0. View

10.

Clemmons D, Camacho-Hubner C, Coronado E, Osborne C . Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990; 127(6):2679-86. DOI: 10.1210/endo-127-6-2679. View

11.

Papa V, Hartmann K, Rosenthal S, Maddux B, Siiteri P, Goldfine I . Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF-II. Mol Endocrinol. 1991; 5(5):709-17. DOI: 10.1210/mend-5-5-709. View

12.

Osborne C, Arteaga C . Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990; 15(1):3-11. DOI: 10.1007/BF01811884. View

13.

Dickson R, Lippman M . Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev. 1987; 8(1):29-43. DOI: 10.1210/edrv-8-1-29. View

14.

Daughaday W . Radioligand assays for insulin-like growth factor II. Methods Enzymol. 1987; 146:248-59. DOI: 10.1016/s0076-6879(87)46027-8. View

15.

Barreca A, Minuto F . Somatomedins: chemical and functional characteristics of the different molecular forms. J Endocrinol Invest. 1989; 12(4):279-93. DOI: 10.1007/BF03349988. View

16.

Bronzert D, Pantazis P, Antoniades H, Kasid A, Davidson N, Dickson R . Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A. 1987; 84(16):5763-7. PMC: 298943. DOI: 10.1073/pnas.84.16.5763. View

17.

Peyrat J, Bonneterre J, Hecquet B, Vennin P, Louchez M, Fournier C . Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer. 1993; 29A(4):492-7. DOI: 10.1016/s0959-8049(05)80137-6. View

18.

Furlanetto R, Marino J . Radioimmunoassay of somatomedin C/insulin-like growth factor I. Methods Enzymol. 1987; 146:216-26. DOI: 10.1016/s0076-6879(87)46023-0. View

19.

Hossenlopp P, Seurin D, Hardouin S, BINOUX M . Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem. 1986; 154(1):138-43. DOI: 10.1016/0003-2697(86)90507-5. View

20.

TOPPER Y, Freeman C . Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev. 1980; 60(4):1049-106. DOI: 10.1152/physrev.1980.60.4.1049. View